Contact Information: For More Information, Contact: James E. Fickenscher CFO Auxilium Pharmaceuticals, Inc. (484) 321-5900 William Q. Sargent, Jr. V.P., IR Auxilium Pharmaceuticals, Inc. (484) 321-5900
Auxilium Pharmaceuticals to Present at the Cowen and Co. 30th Annual Health Care Conference
| Source: Auxilium Pharmaceuticals, Inc.
MALVERN, PA--(Marketwire - March 4, 2010) - Auxilium Pharmaceuticals, Inc. (NASDAQ : AUXL )
today announced that executive management will participate in the Cowen and
Co. 30th Annual Health Care Conference to be held March 8 - 11, 2010 at The
Boston Marriott Copley Place. Mr. Jim Fickenscher, Chief Financial
Officer, is scheduled to present an overview of the Company and its product
pipeline at 10:20a.m. ET on Thursday, March 11, 2010.
To listen to the audio web cast of the presentation during or after the
event, please visit: http://www.auxilium.com. The replay will be available
for ninety days after the event.
About Auxilium
Auxilium Pharmaceuticals, Inc. is a specialty biopharmaceutical company
with a focus on developing and marketing to urologists, endocrinologists,
orthopedists and select primary care physicians. Auxilium markets
XIAFLEX™ (collagenase clostridium histolyticum) for the treatment of
adult Dupuytren's contracture patients with a palpable cord and Testim®
1%, a topical testosterone gel, for the treatment of hypogonadism. Auxilium
has four projects in clinical development. XIAFLEX is in phase IIb of
development for the treatment of Peyronie's disease and is in phase II of
development for treatment of Frozen Shoulder syndrome (Adhesive
Capsulitis). Auxilium's transmucosal film product candidate for the
treatment of overactive bladder (AA4010) and its fentanyl pain product
using its transmucosal delivery system are in phase I of development. The
Company is currently seeking a partner to further develop these product
candidates. Auxilium has rights to additional pain products and products
for hormone replacement and urologic disease using its transmucosal film
delivery system. Auxilium also has options to all indications using XIAFLEX
for non-topical formulations. For additional information, visit
http://www.auxilium.com.
SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF
1995
This release contains "forward-looking-statements" within the meaning of
The Private Securities Litigation Reform Act of 1995, including statements
regarding the Company's intention to present at the Cowen and Co.
30th Annual Health Care Conference; and products in development for
Peyronie's disease, Frozen Shoulder syndrome, overactive bladder, pain,
hormone replacement and urologic disease; and all other statements
containing projections, statements of future performance or expectations,
or statements of plans or objectives for future operations (including
statements of assumption underlying or relating to any of the foregoing).
You can identify these statements by the fact that they use words such as
"believe," "appears," "may," "could," "will," "estimate," "continue,"
"anticipate," "intend," "should," "plan," "expect," and other words and
terms of similar meaning in connection with any discussion of projections,
future performance or expectations, plans or objectives for future
operations (including statements of assumption underlying or relating to
any of the foregoing). Actual results may differ materially from those
reflected in these forward-looking statements due to various factors,
including further evaluation of clinical data, results of clinical trials,
decisions by regulatory authorities as to whether and when to approve drug
applications, and general financial, economic, regulatory and political
conditions affecting the biotechnology and pharmaceutical industries and
those discussed in Auxilium's Annual Report on Form 10-K for the year ended
December 31, 2009 under the heading "Risk Factors," which is on file with
the Securities and Exchange Commission (the "SEC") and may be accessed
electronically by means of the SEC's home page on the Internet at
http://www.sec.gov or by means of Auxilium's home page on the Internet at
http://www.Auxilium.com under the heading "For Investors -- SEC Filings."
There may be additional risks that Auxilium does not presently know or that
Auxilium currently believes are immaterial which could also cause actual
results to differ from those contained in the forward-looking statements.
Given these risks and uncertainties, any or all of these forward-looking
statements may prove to be incorrect. Therefore, you should not rely on any
such factors or forward-looking statements.
In addition, forward-looking statements provide Auxilium's expectations,
plans or forecasts of future events and views as of the date of this
release. Auxilium anticipates that subsequent events and developments will
cause Auxilium's assessments to change. However, while Auxilium may elect
to update these forward-looking statements at some point in the future,
Auxilium specifically disclaims any obligation to do so. These
forward-looking statements should not be relied upon as representing
Auxilium's assessments as of any date subsequent to the date of this
release. This release contains "forward-looking-statements" within the
meaning of The Private Securities Litigation Reform Act of 1995, including
statements regarding the Company's intention to present at the Cowen and
Co. 30th Annual Health Care Conference, and products in development for the
treatment of Dupuytren's contracture, Peyronie's disease and Frozen
Shoulder Syndrome and for pain, hormone replacement and urologic disease.
All statements other than statements of historical facts contained in this
release, including but not limited to, statements regarding future
expectations, plans and prospects for the Company, statements regarding
forward-looking financial information and other statements containing the
words "believe," "may," "could," "will," "estimate," "continue,"
"anticipate," "intend," "should," "plan," "expect," and similar
expressions, as they relate to the Company, constitute forward-looking
statements. Actual results may differ materially from those reflected in
these forward-looking statements due to various factors, including further
evaluation of clinical data, results of clinical trials, decisions by
regulatory authorities as to whether and when to approve drug applications,
and general financial, economic, regulatory and political conditions
affecting the biotechnology and pharmaceutical industries and those
discussed in the Company's Annual Report on Form 10-K for the year ended
December 31, 2009 and the Company's Quarterly Report on Form 10-Q for the
period ended June 30, 2009 under the heading "Risk Factors," which are on
file with the Securities and Exchange Commission (the "SEC") and may be
accessed electronically by means of the SEC's home page on the Internet at
http://www.sec.gov or by means of Auxilium's home page on the Internet at
http://www.Auxilium.com under the heading "Investor Relations -- SEC
Filings." There may be additional risks that Auxilium does not presently
know or that Auxilium currently believes are immaterial which could also
cause actual results to differ from those contained in the forward-looking
statements. Given these risks and uncertainties, any or all of these
forward-looking statements may prove to be incorrect. Therefore, you should
not rely on any such factors or forward-looking statements.
In addition, forward-looking statements provide the Company's expectations,
plans or forecasts of future events and views as of the date of this
release. The Company anticipates that subsequent events and developments
will cause the Company's assessments to change. However, while the Company
may elect to update these forward-looking statements at some point in the
future, the Company specifically disclaims any obligation to do so. These
forward-looking statements should not be relied upon as representing the
Company's assessments as of any date subsequent to the date of this
release.